Hanauske-Abel
Hartmut M. Hanauske-Abel, Edgewater, NJ US
Patent application number | Description | Published |
---|---|---|
20090253777 | Methods of diagnosing and treating hyperproliferative disorders - The invention relates to compositions and methods for diagnosing and treating hyperproliferative disorders using ligands which specifically recognize the hypusine and/or folate binding region of mature eukaryotic translation initiation factor 5A (hypusine-containing eIF-5A). The invention further relates to methods of identifying molecules which displace immunoreagents binding to mature eIF-5A. Such agents are useful for treating hyperproliferative disorders. | 10-08-2009 |
20140073685 | METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased. | 03-13-2014 |
20140206637 | Inhibition of Nonsense Mediated mRNA Decay by Drugs that Prevent Hypusination of Eukaryotic Initiation Factor 5A - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD an inhibitor of NMD and a nonsense suppressor, whereby degradation of NMD susceptible mRNA is decreased and translation termination at a misplaced nonsense codon is blocked. | 07-24-2014 |
Hartmut M. Hanauske-Abel, Englewood Cliffs, NJ US
Patent application number | Description | Published |
---|---|---|
20120225093 | Abrogating HIV-1 Infection via Drug-Induced Reactivation of Apoptosis - The present invention relates to compositions and methods of treating, inhibiting, or controlling HIV infection. | 09-06-2012 |
Hartmut Martin Hanauske-Abel, Englewood Cliffs, NJ US
Patent application number | Description | Published |
---|---|---|
20110039911 | METHOD OF INHIBITING NONSENSE-MEDIATED mRNA DECAY - Provided are methods for treating a NAD comprising administering to a patient suffering from a NAD a composition comprising an eIF5A inhibitor compound in an amount effective to prevent intracellular hypusination of eIF5A, whereby gene expression of NMD-susceptible mRNA is increased. | 02-17-2011 |
H., M. Hanauske-Abel, Englewood Cliffs, NJ US
Patent application number | Description | Published |
---|---|---|
20120095058 | Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses - The present invention discloses compounds and pharmaceutical compositions which are highly effective at inhibiting the accumulation of spliced and unspliced viral transcripts and their utilization for viral protein synthesis at cellular ribosomes, and at inhibiting the formation of the hypusine residue in cellular eIF-5A precursor proteins, the cellular cofactors that render spliced and unspliced viral transcripts translatable at the ribosomes of infectled cells. The invention further relates to methods of using such compounds and pharmaceutical compositions therefrom for inhibiting or preventing viral protein synthesis. Such inhibition cause a dose-dependent release from the virally induced arrest of the otherwise genetically preprogrammed apoptosis of virally infected cells, and in consequence, triggers their apoptotic ablation and the eradication of the chronic infection-mediating provirus integrated into their genome. | 04-19-2012 |